Gritstone Oncology (GRTS) Reaches New 52-Week High at $30.41

Gritstone Oncology Inc (NASDAQ:GRTS)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $30.41 and last traded at $31.08, with a volume of 2783 shares traded. The stock had previously closed at $30.23.

A number of equities analysts recently issued reports on the stock. BTIG Research assumed coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued a “buy” rating and a $26.00 price target on the stock. Barclays assumed coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued an “overweight” rating and a $25.00 price target on the stock. Cowen assumed coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued an “outperform” rating on the stock. Finally, Goldman Sachs Group assumed coverage on shares of Gritstone Oncology in a research note on Tuesday, October 23rd. They issued a “neutral” rating and a $18.00 price target on the stock.

Gritstone Oncology (NASDAQ:GRTS) last announced its quarterly earnings results on Wednesday, November 14th. The company reported ($7.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($6.97). The company had revenue of $0.10 million for the quarter.

In other Gritstone Oncology news, Director Nicholas Simon bought 333,333 shares of the firm’s stock in a transaction on Friday, September 28th. The stock was acquired at an average price of $15.00 per share, with a total value of $4,999,995.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Large investors have recently modified their holdings of the business. Riverhead Capital Management LLC purchased a new position in Gritstone Oncology in the 3rd quarter worth about $141,000. Point72 Asset Management L.P. purchased a new position in Gritstone Oncology in the 3rd quarter worth about $142,000. Partner Investment Management L.P. purchased a new position in Gritstone Oncology in the 3rd quarter worth about $165,000. Pentwater Capital Management LP purchased a new position in Gritstone Oncology in the 3rd quarter worth about $244,000. Finally, Alliancebernstein L.P. purchased a new position in Gritstone Oncology in the 3rd quarter worth about $285,000. 43.52% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This news story was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thelincolnianonline.com/2018/12/08/gritstone-oncology-grts-reaches-new-52-week-high-at-30-41.html.

About Gritstone Oncology (NASDAQ:GRTS)

Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

Recommended Story: How much money do you need to begin day trading?

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply